Treating Community-Acquired Pneumonia

Treating Community-Acquired Pneumonia


Omadacycline is a new antibiotic in the
tetracycline class that blocks protein synthesis. It is active against a number of pathogens
that commonly cause community-acquired bacterial pneumonia including strains that are resistant
to a number of antibiotics. The OPTIC Trial was a phase 3, double-blind, randomized, non-inferiority trial that evaluated
the efficacy and safety of daily omadacycline for the treatment of adults with community-acquired bacterial pneumonia. 774 patients with either clinical signs or
symptoms and imaging consistent with pneumonia were randomized to either omadacycline
or moxifloxacin for 7 to 14 days. The primary efficacy endpoint was early clinical
response at 72 to 120 hours after the first dose of the trial drug. This was defined as improvement in at least
2 of 4 symptoms (cough, sputum production, pleuritic chest pain and dyspnea), and no symptom
deterioration and no rescue antibacterial therapy. Noninferiority was concluded if the lower
limit of the 95% confidence interval exceeded -10%. In the intention to treat analysis, early
clinical response occurred in 81.1% of those receiving omadacycline and 82.7% of those receiving
moxifloxacin. The authors conclude that omadacycline was
non-inferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia. Full trial results are available at NEJM.org

2 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *